Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00008216
Status:
TERMINATED
Last Update Posted:
2014-06-06
First Post:
2001-01-06
Brief Title:
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Sponsor:
Columbia University
Organization:
Columbia University
Study Overview
Official Title:
The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation
Status:
TERMINATED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Poor enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells It also helps stop the patients immune system from rejecting the donors stem cells When the healthy stem cells from a donor are infused into the patient they may help the patients bone marrow make stem cells red blood cells white blood cells and platelets
PURPOSE This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer
PURPOSE This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer
Detailed Description:
OBJECTIVES
Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy
Determine the hematopoietic recovery incidence of chemoradiotherapeutic toxicity relapse graft-versus-host disease and survival of patients treated with this regimen
OUTLINE Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation Patients undergo allogeneic peripheral blood stem cell transplantation on day 0
Patients are followed every 1-2 weeks for 6 months and at 9 12 24 and 36 months
PROJECTED ACCRUAL A total of 62 patients will be accrued for this study within 4 years
Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy
Determine the hematopoietic recovery incidence of chemoradiotherapeutic toxicity relapse graft-versus-host disease and survival of patients treated with this regimen
OUTLINE Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation Patients undergo allogeneic peripheral blood stem cell transplantation on day 0
Patients are followed every 1-2 weeks for 6 months and at 9 12 24 and 36 months
PROJECTED ACCRUAL A total of 62 patients will be accrued for this study within 4 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1891 | None | None | None |
| CPMC-IRB-AAAA5571 | None | None | None |
| CPMC-CAMP-016 | None | None | None |